[go: up one dir, main page]

WO2006025029A3 - Extended release composition of divalproex - Google Patents

Extended release composition of divalproex Download PDF

Info

Publication number
WO2006025029A3
WO2006025029A3 PCT/IB2005/052857 IB2005052857W WO2006025029A3 WO 2006025029 A3 WO2006025029 A3 WO 2006025029A3 IB 2005052857 W IB2005052857 W IB 2005052857W WO 2006025029 A3 WO2006025029 A3 WO 2006025029A3
Authority
WO
WIPO (PCT)
Prior art keywords
extended release
divalproex
release composition
lactose
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2005/052857
Other languages
French (fr)
Other versions
WO2006025029A2 (en
Inventor
Pratik Kumar
Girish Kumar Jain
Ashok Rampal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ranbaxy Laboratories Ltd
Original Assignee
Ranbaxy Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Laboratories Ltd filed Critical Ranbaxy Laboratories Ltd
Publication of WO2006025029A2 publication Critical patent/WO2006025029A2/en
Publication of WO2006025029A3 publication Critical patent/WO2006025029A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention relates to an extended release pharmaceutical composition comprising divalproex sodium and lactose wherein the amount of lactose is less than 8% w/w of the total weight of the pharmaceutical composition.
PCT/IB2005/052857 2004-08-31 2005-08-31 Extended release composition of divalproex Ceased WO2006025029A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1649DE2004 2004-08-31
IN1649/DEL/2004 2004-08-31

Publications (2)

Publication Number Publication Date
WO2006025029A2 WO2006025029A2 (en) 2006-03-09
WO2006025029A3 true WO2006025029A3 (en) 2006-05-18

Family

ID=35636703

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2005/052857 Ceased WO2006025029A2 (en) 2004-08-31 2005-08-31 Extended release composition of divalproex

Country Status (1)

Country Link
WO (1) WO2006025029A2 (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000037055A1 (en) * 1998-12-18 2000-06-29 Abbott Laboratories Controlled release formulation of divalproex sodium
WO2002051401A2 (en) * 2000-12-22 2002-07-04 Abbott Laboratories Controlled release formulations of divalproex sodium
WO2002051402A1 (en) * 2000-12-22 2002-07-04 Abbott Laboratories Controlled release formulation of divalproex sodium
WO2003103635A1 (en) * 2002-06-07 2003-12-18 Ranbaxy Laboratories Limited Extended release formulation of divalproex sodium
WO2004071424A2 (en) * 2003-02-05 2004-08-26 Teva Pharmaceutical Industries, Ltd. Immediate release formulation of n-(2-propylpentanoyl)glycinamide

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000037055A1 (en) * 1998-12-18 2000-06-29 Abbott Laboratories Controlled release formulation of divalproex sodium
WO2002051401A2 (en) * 2000-12-22 2002-07-04 Abbott Laboratories Controlled release formulations of divalproex sodium
WO2002051402A1 (en) * 2000-12-22 2002-07-04 Abbott Laboratories Controlled release formulation of divalproex sodium
WO2003103635A1 (en) * 2002-06-07 2003-12-18 Ranbaxy Laboratories Limited Extended release formulation of divalproex sodium
WO2004071424A2 (en) * 2003-02-05 2004-08-26 Teva Pharmaceutical Industries, Ltd. Immediate release formulation of n-(2-propylpentanoyl)glycinamide

Also Published As

Publication number Publication date
WO2006025029A2 (en) 2006-03-09

Similar Documents

Publication Publication Date Title
MX2007004294A (en) Pharmaceutical compositions comprising levetiracetam and process for their preparation.
WO2004093884A3 (en) High drug load mesalazine sachet
WO2005089729A3 (en) Galenic formulations of organic compounds
CA2469369A1 (en) Compositions containing both sedative and non-sedative antihistamines
WO2004078712A3 (en) Isoquinoline derivatives and methods of use thereof
WO2003053359A3 (en) 1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders
EP1424994A4 (en) Preparation of sustained release pharmaceutical composition
WO2007146248A3 (en) Stable laquinimod preparations
WO2001090091A8 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
EP1578403A4 (en) Modified release compositions of milnacipran
IL188758A (en) Aryl- and heteroaryl-substituted 2,3,4,5-tetrahydro-1h-benzo(c)azepines, pharmaceutical compositions comprising them and methods of preparation
EP1539122A4 (en) PHARMACEUTICAL COMPOSITIONS OF AQUEOUS 2,6-DIISOPROPYLPHENOL
WO2008006514A8 (en) Active ingredient combinations with insecticidal and acaricidal properties
WO2006024479A3 (en) Pharmaceutical multiparticulate compositions comprising mycophenolic acid or mycophenolate sodium and combination compositions with rapamycin
WO2007132134A3 (en) Compositions comprising at least one naphthoic acid derivative and benzoyl peroxide, methods for preparing same, and uses thereof
AU2003297840A1 (en) Chemopreventive and therapeutic aspects of polyphenolic compositions and assays
IL182811A (en) Dicarboxamide derivatives, compositions, uses and methods of preparation thereof
AU2002256304A1 (en) Compositions for delivery of compounds to cells and methods of use
WO2006056696A3 (en) 2-alcoxy-3,4,5-trihydroxy-alkylamides, preparation thereof, compositions containing them and use thereof
HUP0401633A3 (en) Use of irbesartan for the preparation of pharmaceutical compositions that are used to prevent or treat pulmonary hypertension
AU2002350832A1 (en) Use of irbesartan for the preparation of medicaments that are used to prevent or treat pulmonary hypertension
UA94025C2 (en) Use of antagonists of the cb1 receptor for the manufacture of a composition useful for the treatment of liver fibrosis
WO2005110413A3 (en) Medicaments containing n-sulfamoyl-n'-arylpiperazines for the prophylaxis or treatment of obesity and related conditions
WO2006025029A3 (en) Extended release composition of divalproex
WO2004048381A3 (en) Pyrazoloazepine compounds as pharmaceutical agents

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1637/DELNP/2007

Country of ref document: IN

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase